Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05921162 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection

Study acronym: EXTEND
StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 25, 2025 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 2024 to May 2025v6
  2. 2 versions Re-verified since Jul 31, 2023, no change to tracked fieldsv4-v5
  3. Start date changed from estimate of Jun 2023 to Jul 14, 2023v3
  4. Primary endpoints revised (2)
    • Secondary endpoints revised (2)
    • Study title shortened, about 1 word
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study "A Long-Term Follow-Up Study in Subjects Who Received an Adeno-Associated Viral Vector Serotype 2 Containing the Multi-Characteristic Opsin Gene (vMCO-I) Administered Via Intravitreal Injection" is an observational study and will be conducted following Good Clinical Practice (GCP)- International Conference on Harmonization (ICH) guidelines. Eligible subjects satisfying all inclusion and none of the exclusion criteria will be enrolled. All subject who completed the parent clinical study (NSCT/CT/18/01) will undergo safety and efficacy assessments up to 5 years post study drug injection
Trial Details
NCT Number NCT05921162
Lead Sponsor Nanoscope Therapeutics Inc.
Conditions
(from sponsor)		 Retinitis Pigmentosa, Retinal Disease, Retinal Degeneration
Related terms Retinal Degeneration, Retinal Diseases, Retinitis Pigmentosa
Enrollment 11 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov